Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome Sciences Nets $11.6M in Private Placement

NEW YORK (GenomeWeb News) — OncoMethylome Sciences has raised €8.4 million ($11.6 million) by selling 1.3 million new shares at €6.29 a share to three investors in a private placement, the cancer biomarker company said today.
 
The company plans to use the funding to continue to develop biomarkers for use in companion diagnostic tests, cancer detection, and treatment.
 
The investment, which accounts for a 10.1 percent stake in the new company, came from AGF Private Equity, APG Investments, and Fortis Investments Management. AGF bought a 6 percent stake in OncoMethylome, while APG Investments and Fortis acquired a 2.4 percent and 1.7 percent stake in the company, respectively.
 
Liege, Belgium-based OncoMethylome noted that it currently has no financial debt, and as of the date of the placement it holds roughly €30 million in cash and cash equivalents.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.